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Abstract
Objectives—To assess the prevalence, characteristics, and risk of sensorineural hearing loss 
(SNHL) through 18 years of age in children with congenital CMV infection identified through 
hospital-based newborn screening who were asymptomatic at birth compared to uninfected 
children.
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Methods—We included 92 case-patients and 51 controls assessed using auditory brainstem 
response and behavioral audiometry. We used Kaplan-Meier survival analysis to estimate 
prevalence of SNHL, defined as ≥25 dB hearing level (HL) at any frequency, and Cox proportional 
hazards regression analyses to compare SNHL risk between groups.
Results—At the end of follow-up, SNHL prevalence was 25% (95% CI: 17–36%) among case-
patients and 8% (95% CI: 3–22%) in controls (hazard ratio (HR): 4.0; 95% CI: 1.2–14.5; p-
value=0.02). Among children without SNHL by age 5 years, the risk of delayed-onset SNHL was 
not significantly greater for case-patients than for controls (HR: 1.6; 95% CI: 0.4–6.1; P=0.5). 
Among case-patients, the risk of delayed-onset SNHL was significantly greater among those with 
unilateral congenital/early-onset loss than those without (hazard ratio: 6.9; 95% CI: 2.5–19.1; 
P<0.01). At the end of follow-up, the prevalence of severe to profound bilateral SNHL among 
case-patients was 2% (95% CI: 1–9%).
Conclusions—Delayed-onset and progression of SNHL among children with asymptomatic 
congenital CMV infection continued to occur throughout adolescence. However, the risk of 
developing SNHL after age 5 years among case-patients was not different than in uninfected 
children. An estimated 2% of case-patients developed SNHL severe enough to be candidates for 
cochlear implantation.
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BACKGROUND
Congenital cytomegalovirus (CMV) infection causes a spectrum of impairments, including 
sensorineural hearing loss (SNHL), vision loss, and developmental delays. In the United 
States, an estimated 20,000 (0.5%) children are born with congenital CMV infection 
annually.1, 2 Although the majority (85–90%) appear asymptomatic at birth, SNHL may be 
present at birth, progress in severity, or develop later.3
The burden of SNHL in children with asymptomatic congenital CMV infection at birth 
remains incompletely characterized, and the extent to which these children remain at risk of 
SNHL throughout childhood and adolescence is not well described. Previous studies have 
documented delayed-onset SNHL among children with asymptomatic congenital CMV 
infection up to age 15 years.4–7 However, data from controlled studies with follow-up 
through adolescence are lacking. Studies that also included uninfected children had follow-
up until 5–7 years and did not attempt to compare the risk of delayed-onset SNHL between 
children with asymptomatic congenital CMV infection and uninfected children.4–6, 8, 9 In 
this study, we assessed prevalence, characteristics, and risk of SNHL through age 18 years in 
children with congenital CMV infection identified through hospital-based newborn 
screening who were asymptomatic at birth compared to uninfected children.
PATIENTS AND METHODS
During 1982–1992, 32,543 newborns delivered at Women’s Hospital of Texas, Houston TX, 
were screened for congenital CMV infection via urine culture collected within 3 days of life, 
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as described previously.10, 11 Of 135 (0.4%) CMV-positive newborns, 92 (68%) were 
enrolled in a longitudinal study as asymptomatic case-patients, e.g. they had no CMV-related 
signs at birth (purpura/petechiae, jaundice, hepatosplenomegaly, microcephaly, elevated liver 
enzymes, bilirubinemia, hemolytic anemia or thrombocytopenia). Fifty-one uninfected 
newborns whose parents agreed to participate in the study were enrolled as controls, 42 
(82%) were among CMV-negative newborns randomly pre-selected within 6 days of birth of 
a CMV-positive newborn (n=298), and 9 (18%) were siblings of referred CMV-positive 
infants or born to women diagnosed with CMV infection during pregnancy. We analyzed 
data from serial audiological assessments from birth to 18 years of age. The Institutional 
Review Board for Human Subject Research for Baylor College of Medicine and Affiliated 
Hospitals approved the study protocol.
Audiologic assessments were conducted by audiologists unaware of subject CMV status and 
included auditory brainstem response (ABR), behavioral audiometry (0.25 to 8 kHz), and 
tympanometry.10 ABR testing included click and frequency-specific tone-burst stimuli. We 
combined the latter with frequency-specific pure-tone air conduction results obtained by 
behavioral audiometry after subtracting 10 dB for 0.5, 1 and 8 kHz, and 0 dB for 2 and 4 
kHz from the tone-burst levels.12 We defined SNHL as ≥25 dB hearing level (HL) for the 
ABR click or at any frequency for the corrected tone-burst or pure-tone air conduction 
results. Because middle ear disorder can cause transient conductive hearing loss, we 
excluded assessments with tympanometry type B.
We analyzed SNHL by age at onset, laterality, and progression. We categorized SNHL 
among case-patients for each ear as congenital/early-onset when detected in the first ABR 
assessment at age ≤12 months and confirmed in subsequent assessments, or as delayed-onset 
when detected after one or more assessments with normal hearing. We classified SNHL as 
unilateral if it was present in one ear or bilateral if present in both ears. We defined SNHL as 
progressive when a change to worse hearing occurred between the first detection of SNHL 
and the last assessment, or stable when there was no change between these two assessments. 
We defined fluctuations as changes to worse or better hearing level between consecutive 
assessments: an absolute difference of ≥20 dB in one or more frequencies, ≥10 dB across 
any 2 or 3 adjacent frequencies, ≥10 dB in the average of the pure-tone thresholds at 0.5, 1, 
2, and 4 kHz (four-frequency average), or a change from “hearing” to “no response” or vice-
versa at 3 adjacent frequencies.13
We categorized SNHL severity for each ear using the ABR click result or the four-frequency 
average, as follows: slight (16 to 25 dB HL), mild (26 to 40 dB HL), moderate (41 to 55 dB 
HL), moderately severe (56 to 70 dB HL), severe (71 to 90 dB HL) and profound (91 dB HL 
or greater) hearing loss.14 We classified children with ≥25 dB HL in any frequency without 
affecting the four-frequency average as having SNHL at isolated frequencies. We described 
SNHL severity in the poorer- and better-hearing ears. For example, a child with unilateral 
SNHL could be categorized as having profound loss in the poorer-hearing ear but normal 
hearing in the better-hearing ear. Characterization by poorer-hearing ear provides a more 
complete description of SNHL burden as it includes children with unilateral loss. However, 
eligibility criteria for health insurance coverage for audiologic services may require bilateral 
loss15, which is described by better-hearing ear assessment. To estimate need for audiologic 
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services, we assumed hearing aids would be recommended for children with unilateral or 
bilateral SNHL ≥40 db HL, and cochlear implants for those with bilateral SNHL ≥70 db 
HL.15
We compared demographic and birth characteristics among case-patients and controls using 
Chi-square or exact test. To deal with loss to follow-up at varying ages, we used Kaplan-
Meier survival analysis to estimate the proportion of children with SNHL by age. We 
calculated hazard ratios (HR) using Cox proportional hazards regression analyses to 
compare SNHL risk between groups. We considered results with a p-value <0.05 statistically 
significant. For analyses, we used SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).
RESULTS
The majority of the 92 case-patients and 51 controls were male (58% vs. 67%), born at ≥37 
weeks gestation (88% vs. 98%) to mothers who were <30 years of age (63% vs. 53%), non-
Hispanic White (82% vs. 86%), married (95% vs. 100%), and multipara (78% vs. 70%), 
with no statistically significant differences between the 2 groups (p>0.05 for all). A higher 
proportion of case-patients’ mothers had ≥1 living children at the time of birth than control’s 
mothers (68% vs. 49%; p<0.05).
Among the 92 case-patients, the median number of audiologic assessments was 7 (range: 1–
17); the median age at first ABR evaluation was 2.4 months (range: 4 days-11.5 months), 
after which 6 (6%) case-patients without SNHL were lost to follow-up. The remaining 86 
(94%) case-patients had a median of 8 assessments, with the last one at a median age of 17 
years (range: 9 months-18 years); 3 (3%) at 0–3 years, 5 (6%) at 6–9 years, and 78 (91%) at 
12–18 years. Among the 51 controls, the median number of audiologic assessments was 3 
(range: 1–8); the median age at the first assessment was 3 years (range: 1 month-14 years). 
Among 41 controls with ≥2 assessments, the median age at last assessment was 17 (range: 
1–18) years; 1 (2%) at 1 year, 2 (4%) at 6–9 years, and 38 (93%) at 12–18 years.
Using survival analysis, we estimated the proportion of children with SNHL increased from 
7% at age 3 months to 14% at 5 years and 25% at 18 years, among case-patients, and from 
0% at 5 years to 8% at 18 years, among controls (Table 1). SNHL risk from birth through 18 
years was 4-fold greater among case-patients compared to controls (HR: 4.0; 95% CI: 1.2–
14.5; p-value=0.02). SNHL risk from 3 months to 18 years was 3-fold greater among case-
patients compared to controls (HR: 3.0; 95% CI: 0.9–10.5; p-value=0.08), but not 
statistically significant. SNHL risk from 6 to 18 years was 1.6-fold greater among case-
patients compared to controls, but not statistically significant (HR: 1.6; 95% CI: 0.4–6.1; p-
value=0.5) (Figure 1).
Among case-patients, 9 (10%) were ultimately classified with congenital/early-onset SNHL. 
Although 23 (25%) of 92 case-patients had had ≥25 dB HL detected at the first ABR 
(screening) assessment, 14 (61%) had normal hearing in both ears in subsequent 
assessments. Most (8/9) case-patients with confirmed congenital/early-onset SNHL 
presented with unilateral loss but the majority (6/8) subsequently developed delayed-onset 
SNHL in the contralateral ear. In contrast, only 11 (14%) of 77 case-patients without 
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congenital/early-onset SNHL who had ≥2 assessments had delayed-onset SNHL (Figure 2). 
Among case-patients, the risk of delayed-onset SNHL was significantly greater among those 
with unilateral congenital/early-onset loss than those without (HR: 6.9; 95% CI: 2.5–19.1). 
Overall, the proportion of case-patients with SNHL that had bilateral loss increased from 
22% at 12 months of age to 50% at last assessment (Table 1). The median interval from 
unilateral to bilateral SNHL was 4 years (range: 4 months–18 years).
Worsening of SNHL in affected ears was common; among 20 case-patients with SNHL, 13 
(65%) had progressive loss in the poorer-hearing ear, 5 (25%) had stable loss, and 2 (10%) 
were indeterminate. Among 10 case-patients with bilateral SNHL, 4 (40%) had progressive 
loss in the better-hearing ear, 3 (15%) had stable loss without fluctuations, and 3 (15%) were 
indeterminate. Among 10 case-patients with SNHL who had fluctuations, progression 
occurred in all but one. In all case-patients with SNHL, the initially poorer-hearing ears 
remained the more severely affected ear throughout follow-up.
SNHL severity increased with age. At the last assessment, 12 (60%) of the 20 case-patients 
with SNHL had moderate or worse loss in the poorer-hearing ear and 4 of the 10 case-
patients with bilateral SNHL had moderate or worse loss in the better-hearing ear (Figure 3). 
SNHL severity was greater among the 9 case-patients with congenital/early-onset SNHL, of 
whom 8 (89%) had profound loss in the poorer-hearing ear at last assessment. The 8 case-
patients and 3 controls diagnosed with delayed-onset SNHL after age 5 years all had mild or 
lesser degree of loss in the poorer-hearing ear, among whom 3 (38%) and 1 (33%), 
respectively, had audiograms suggestive of noise-induced loss.
We estimated the proportion of case-patients that would require hearing aids increased from 
10% at age 12 months to 14% at 18 years (Supplementary material). The proportion of case-
patients that would meet current candidacy criteria for cochlear implants increased from 1% 
at age 25 months to 2% at 5 years, remaining unchanged after that age. In considering more 
expansive criteria for cochlear implantation, 5% of case-patients had SNHL ≥70 dB HL in 
the poorer-hearing ear by age 12 months, increasing to 13% at 18 years.
DISCUSSION
In this study of children with congenital CMV infection identified through hospital-based 
newborn screening who were asymptomatic at birth, prevalence and severity of SNHL 
increased throughout childhood. Children with asymptomatic congenital CMV infection 
who had unilateral congenital/early-onset SNHL were at greater risk of subsequent delayed-
onset loss in the normal-hearing ear compared to those without any SNHL in the first year of 
life. Many children with unilateral loss present with bilateral loss later and/or experience 
progressive hearing loss, e.g. from mild/moderate to severe or profound hearing loss. 
Therefore, ongoing audiological monitoring is critical so that they can receive appropriate 
interventions in a timely manner.
From age 3 months to 5 years, the prevalence of SNHL doubled among case-patients, from 
7% to 14% but remained at 0% among controls. From 6 years to 18 years, the changes in 
SNHL prevalence were similar between the case-patients and controls, 11% and 8%, 
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respectively. This finding is consistent with the 13% prevalence reported nationally among 
children 6–19 years of age in the United States.16 Therefore, it appears that the risk of 
delayed-onset SNHL among school-aged case-patients was not appreciably higher than in 
the comparison group. Larger controlled studies will be important to confirm these findings 
and inform future guidance on optimal duration of audiologic monitoring for children with 
asymptomatic congenital CMV infection. The possibility that routine monitoring for SNHL 
among children with congenital CMV infection who have normal hearing may not be 
necessary beyond 5 years of age is of clinical importance.
We observed 65% of our case-patients with SNHL had progressive loss. Although we used 
strict criteria based on ototoxicity monitoring studies13 for categorizing SNHL as 
progressive, the proportion with progressive SNHL in our study was higher than the 20% 
estimated in a recent meta-analysis.17 Referral bias in the studies included in the meta-
analysis likely contribute to this difference. Some studies were based on cohorts of children 
identified with asymptomatic congenital CMV infection due to diagnosis of SNHL at birth 
or primary maternal CMV infection during pregnancy.7, 18–20 Thus, some children were 
likely at greater risk of more severe SNHL at onset than the entire population of infants with 
asymptomatic congenital CMV infection. Consistent with this, the same meta-analysis17 
estimated that a higher proportion of children with asymptomatic congenital CMV infection 
and SNHL have bilateral severe to profound loss compared to our study (42% vs. 16% by 
age 5 years). Studies in which a larger proportion of children present with profound loss 
when SNHL is detected would have relatively fewer children who could experience SNHL 
progression.
CMV-related SNHL in children with congenital CMV infection who passed hearing 
screening tests in the first month of life has been detected as early as 3 months of age.21 
Newborn hearing screening programs will not detect all infants with CMV-related hearing 
loss. In our study, at least 25% of case-patients with SNHL by age 5 would not have been 
identified by newborn hearing screening. This proportion is lower than the 50% found in a 
large hospital-based newborn screening study with follow-up through age 6 years21, albeit 
higher than the 9% estimated in a recent meta-analysis.17 Comparisons of delayed-onset 
SNHL among children with asymptomatic congenital CMV infection across studies are 
complicated by heterogeneity in case ascertainment methods and duration of follow-up.22 
Currently, an estimated one third of all children with bilateral SNHL ≥40 dB HL by age 4 
years are not identified by newborn hearing screening.23 The ongoing CMV and Hearing 
Multicenter Screening Study will provide population-based estimates of prevalence of 
congenital CMV infection and CMV-related SNHL through age 4 years in the United 
States.24 These data will be useful to inform the potential benefit of newborn screening for 
congenital CMV infection in identifying children at risk of delayed-onset SNHL who are 
missed by newborn hearing screening.
Identifying the etiology of a hearing loss may affect clinical management and can provide 
reassurance to families.23 Diagnosis of CMV-related SNHL depends on diagnosis of 
congenital CMV infection which requires laboratory testing on a specimen collected within 
3 weeks of life. However, full audiologic evaluation to confirm or rule out hearing loss may 
not be conducted until later in infancy when laboratory testing can no longer confirm 
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congenital infection. Thus, targeted CMV testing among newborns who refer in newborn 
hearing screening has been explored.25–28 In the United Kingdom, this approach was found 
to be feasible and acceptable within the newborn hearing screening program, and did not 
appear to result in increased parental anxiety.28 In Utah, which implemented a policy in 
2013 mandating CMV testing for all infants who fail newborn hearing screening26, an 
improvement in follow-up rates of all infants who fail the hearing screening was reported. 
This testing strategy has the potential to increase identification of newborns with SNHL with 
symptomatic congenital CMV infection who would be eligible for antiviral treatment who 
might otherwise have gone unrecognized as well as infants with asymptomatic 
infection.29, 30 However, the efficacy of antiviral treatment in preventing hearing 
deterioration among children with asymptomatic infection has not been systematically 
studied. Therefore, antiviral treatment is not currently recommended for routine use in this 
population.29 More data on the feasibility and benefits of targeted CMV testing are likely to 
become available as this approach is more widely adopted.
Our study had limitations. Our sample size was too small to detect statistically significant 
differences in SNHL risk after age 3 months. We may have underestimated SNHL risk 
among case-patients and controls because of loss of follow-up, particularly among children 
with only a single assessment at younger age. Not all CMV-positive newborns identified 
through screening were enrolled. However, universal newborn hearing screening was not 
routinely done during 1982–1992, thus, it is unlikely that there were systematic biases in the 
enrollment of participants by hearing status that would have affected our estimates. 
Although our control group had fewer audiological assessments and the first assessment at 
an older age compared to case-patients, it does not affect our estimates of delayed-onset 
SNHL because the age at last assessment was similar for both groups. Our control group 
included a small number of children selected among uninfected siblings of referred CMV-
positive infants. Analyses including the control group consisting only of those selected 
among CMV-negative screened newborns resulted in similar findings. Thus, although the 
small number of controls may have limited the power of the study to detect some statistically 
significant differences, the control group appears to have been appropriately valid for 
comparisons. We were unable to precisely determine if SNHL was congenital or delayed-
onset because not all case-patients had hearing evaluations in the first month of life. In 
addition, some infants only had click-evoked ABR without frequency-specific tone burst 
stimuli, which can result in false-negative results. Other than ruling out the administration of 
gentamicin to premature case-patients, we were unable to fully investigate other etiologies of 
SNHL. Data on genetic testing and noise exposure were not available and the audiologic 
assessments did not consistently include testing at 3 and 6 kHz, which could have aided in 
the evaluation of noise-induced SNHL.
CONCLUSIONS
The burden of CMV-related SNHL is substantial considering the impact of SNHL on 
children’s development and academic achievement, and their need for ongoing audiologic 
monitoring and interventions. We estimate that approximately 5% of children with 
asymptomatic congenital CMV infection, about 900 children annually, have SNHL ≥70 dB 
HL in at least one ear by age 12 months and half of these meet current candidacy criteria for 
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cochlear implantation. As cochlear implant technologies and indications for their use 
continue to evolve, the number of children with asymptomatic congenital CMV infection 
and SNHL who might be considered candidates for cochlear implants could increase. 
Newborn screening for congenital CMV infection has the potential to identify children at 
risk for CMV-related SNHL who currently go unrecognized and who might benefit from 
earlier intervention.31 Further investigation of the age of onset and risk factors for SNHL in 
children with asymptomatic congenital CMV infection are needed to inform evaluation of 
the potential costs and benefits of CMV screening.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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What’s Known on This Subject
The extent to which children with congenital CMV infection who are asymptomatic at 
birth remain at risk for delayed-onset and progressive sensorineural hearing loss (SNHL) 
throughout childhood is not well established.
What This Study Adds
SNHL progression occurred through adolescence. SNHL risk after age 5 years was not 
significantly higher than in uninfected children. Overall, 2% of children with 
asymptomatic congenital CMV infection have severe enough bilateral SNHL to 
potentially meet cochlear implantation candidacy.
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Figure 1. 
Sensorineural hearing loss among children with asymptomatic congenital CMV infection 
and controls
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Figure 2. 
Delayed-onset sensorineural hearing loss among children with asymptomatic congenital 
CMV infection with and without unilateral congenital/early-onset hearing loss
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Figure 3. 
Cumulative number of children with asymptomatic congenital CMV infection with 
sensorineural hearing loss (n=20) by age and sensorineural hearing loss severity in the 
poorer- and better-hearing ears
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